EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial

Clémence Bertold iD, Eric Fontas, Tanya Singh iD, Nadia Gastaut, Sandra Ruitort, Sylvia Wehrlen Pugliese, Thierry Passeron iD

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19455 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Clémence Bertold und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, CHU Nice, Université Côte d'Azur, Nice, France. Hauptthemen laut MEDLINE: Quality of Life, Melanosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma. Its efficacy has never been matched before, but it is tempered by frequent adverse effects.

Objective

To assess the efficacy and tolerance of a New Trio (NT) combination with isobutylamido‐thiazolyl‐resorcinol, retinoic acid and cortosteroid compared to KT.

Methods

We conducted a 24‐week monocentric trial, randomized, double‐blind, controlled versus KT, with 40 melasma patients. NT and KT were applied for 12 weeks and associated with the same sunscreen applied for 24 weeks. The primary endpoint was the modified Melasma Area Severity Index (mMASI) at 12 weeks. Patient quality of life was investigated using MelasQoL.

Results

After 12 weeks, KT and NT groups both demonstrated a significant improvement in mMASI, respectively −2.84 (SE 0.69, p < 0.0002) and −4.33 (SE 0.71, p < 0.0001). The mean difference between the two groups was −1.49 (IC 95% −3.52 to 0.54, p = 0.14). MelasQoL improvement was −6.66 (SE 3.29, p = 0.0515) with KT and −12.57 (SE 3.29, p = 0.0006) with NT.

Conclusion

The NT combination appears to be an effective treatment option for treating melasma and could be considered as a well‐tolerated alternative to KT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMelanosisHumansProspective StudiesTretinoinTreatment OutcomeEmollientsHydroquinones

Substanzen

TretinoinEmollientsHydroquinones

Autor:innen und Institutionen

  • Department of Dermatology, CHU Nice, Université Côte d'Azur, Nice, France.
  • Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France.
  • Pharmacy Department, CHU Nice, Université Côte d'Azur, Nice, France.
  • INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.

ORCID-Profile: Clémence Bertold, Tanya Singh, Thierry Passeron

Zitieren

APA

Bertold, C., Fontas, E., Singh, T., Gastaut, N., Ruitort, S., Wehrlen Pugliese, S., & Passeron, T. (2023). Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19455

Vancouver

Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, Wehrlen Pugliese S, et al. Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19455

BibTeX
@article{Bertold2023,
  author = {Bertold, Clémence and Fontas, Eric and Singh, Tanya and Gastaut, Nadia and Ruitort, Sandra and Wehrlen Pugliese, Sylvia and Passeron, Thierry},
  title = {Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19455}
}
Kostenlos starten →